201 related articles for article (PubMed ID: 12637475)
1. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.
Cheung IY; Lo Piccolo MS; Kushner BH; Kramer K; Cheung NK
J Clin Oncol; 2003 Mar; 21(6):1087-93. PubMed ID: 12637475
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.
Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK
Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395
[TBL] [Abstract][Full Text] [Related]
3. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.
Cheung IY; Lo Piccolo MS; Kushner BH; Cheung NK
J Clin Oncol; 2003 Oct; 21(20):3853-8. PubMed ID: 14551304
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
Cheung IY; Cheung NK
Clin Cancer Res; 2001 Jun; 7(6):1698-705. PubMed ID: 11410509
[TBL] [Abstract][Full Text] [Related]
5. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.
Cheung NK; Kushner BH; Cheung IY; Kramer K; Canete A; Gerald W; Bonilla MA; Finn R; Yeh SJ; Larson SM
J Clin Oncol; 1998 Sep; 16(9):3053-60. PubMed ID: 9738575
[TBL] [Abstract][Full Text] [Related]
6. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.
Cheung NK; Ostrovnaya I; Kuk D; Cheung IY
J Clin Oncol; 2015 Mar; 33(7):755-63. PubMed ID: 25559819
[TBL] [Abstract][Full Text] [Related]
8. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.
Cheung NK; Cheung IY; Kushner BH; Ostrovnaya I; Chamberlain E; Kramer K; Modak S
J Clin Oncol; 2012 Sep; 30(26):3264-70. PubMed ID: 22869886
[TBL] [Abstract][Full Text] [Related]
9. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
[TBL] [Abstract][Full Text] [Related]
10. Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.
Cheung NK; Cheung IY; Kramer K; Modak S; Kuk D; Pandit-Taskar N; Chamberlain E; Ostrovnaya I; Kushner BH
Int J Cancer; 2014 Nov; 135(9):2199-205. PubMed ID: 24644014
[TBL] [Abstract][Full Text] [Related]
11. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
[TBL] [Abstract][Full Text] [Related]
12. GD2 synthase: a new molecular marker for detecting neuroblastoma.
Lo Piccolo MS; Cheung NK; Cheung IY
Cancer; 2001 Aug; 92(4):924-31. PubMed ID: 11550167
[TBL] [Abstract][Full Text] [Related]
13. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
14. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Kramer K; Modak S; Yataghene K; Cheung NK
Oncoimmunology; 2015 Jul; 4(7):e1016704. PubMed ID: 26140243
[TBL] [Abstract][Full Text] [Related]
15. Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma.
Cheung IY; Vickers A; Cheung NK
Int J Cancer; 2006 Jul; 119(1):152-6. PubMed ID: 16450393
[TBL] [Abstract][Full Text] [Related]
16. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.
Cheung NK; Sowers R; Vickers AJ; Cheung IY; Kushner BH; Gorlick R
J Clin Oncol; 2006 Jun; 24(18):2885-90. PubMed ID: 16682723
[TBL] [Abstract][Full Text] [Related]
17. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
Hoon DS; Kuo CT; Wen S; Wang H; Metelitsa L; Reynolds CP; Seeger RC
Am J Pathol; 2001 Aug; 159(2):493-500. PubMed ID: 11485908
[TBL] [Abstract][Full Text] [Related]
18. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
Cheung IY; Sahota A; Cheung NK
Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
[TBL] [Abstract][Full Text] [Related]
19. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
20. Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma.
Cheung NK; Guo HF; Heller G; Cheung IY
Clin Cancer Res; 2000 Jul; 6(7):2653-60. PubMed ID: 10914706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
